Ken Griffin Bio Atla, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio Atla, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 800 shares of BCAB stock, worth $328. This represents 0.0% of its overall portfolio holdings.

Number of Shares

800

Previous 500 60.0%

Holding current value

$328

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.59 - $2.37 $45,440 - $182,530	77,017 Added 35656.02%	77,233 $45,000
Q3 2024 Nov 14, 2024	SELL	$1.17 - $2.05 $216,544 - $379,416	-185,081 Reduced 99.88%	216 $0
Q2 2024 Aug 14, 2024	BUY	$1.37 - $3.92 $154,344 - $441,627	112,660 Added 155.1%	185,297 $253,000
Q1 2024 May 15, 2024	SELL	$1.88 - $3.46 $955 - $1,757	-508 Reduced 0.69%	72,637 $249,000
Q4 2023 Feb 14, 2024	SELL	$1.27 - $3.18 $52,710 - $131,982	-41,504 Reduced 36.2%	73,145 $179,000
Q3 2023 Nov 14, 2023	SELL	$1.7 - $3.07 $30,168 - $54,480	-17,746 Reduced 13.4%	114,649 $194,000
Q2 2023 Aug 14, 2023	SELL	$2.83 - $3.87 $1.08 Million - $1.47 Million	-380,239 Reduced 74.17%	132,395 $397,000
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $1.03 Million - $3.68 Million	446,091 Added 670.38%	512,634 $1.37 Million
Q4 2022 Feb 14, 2023	SELL	$6.29 - $11.01 $87,896 - $153,853	-13,974 Reduced 17.36%	66,543 $548,000
Q3 2022 Nov 14, 2022	SELL	$2.94 - $11.87 $289,210 - $1.17 Million	-98,371 Reduced 54.99%	80,517 $620,000
Q2 2022 Aug 15, 2022	BUY	$2.13 - $5.38 $165,875 - $418,972	77,876 Added 77.1%	178,888 $510,000
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $256,825 - $1.1 Million	58,636 Added 138.37%	101,012 $505,000
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $805,144 - $1.31 Million	42,376 New	42,376 $0
Q3 2021 Nov 15, 2021	SELL	$29.44 - $43.74 $4.5 Million - $6.69 Million	-152,999 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$38.07 - $56.17 $2.63 Million - $3.88 Million	69,080 Added 82.32%	152,999 $0
Q1 2021 May 17, 2021	SELL	$32.41 - $70.91 $3.29 Million - $7.19 Million	-101,403 Reduced 54.72%	83,919 $4.27 Million
Q4 2020 Feb 16, 2021	BUY	$31.02 - $35.16 $5.75 Million - $6.52 Million	185,322 New	185,322 $6.3 Million

Others Institutions Holding BCAB

# of Institutions

Shares Held

23.4M

Call Options Held

30.8K

Put Options Held

57K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $14.9M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account